Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS Registry.
Disability trajectories
Italian MS Register
Late onset
Multiple sclerosis
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
03 Jan 2024
03 Jan 2024
Historique:
received:
25
09
2023
accepted:
08
12
2023
revised:
07
12
2023
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
3
1
2024
Statut:
aheadofprint
Résumé
Generally infrequent, multiple sclerosis (MS) with late onset (LOMS) is characterized by an onset over the age of 50 and a mainly progressive course, while relapsing-remitting (RR) forms are less frequently observed and explored. This study aimed to characterize a large cohort of MS patients with RRMS at onset to assess the baseline factors related to the worst disability trajectories and explore the role of LOMS. The data were extracted from the Italian MS Register (IMSR). Disability trajectories, defined using at least two and up to twenty expanded disability status scale (EDSS) assessments annually performed, were implemented using group-based trajectory models (GBTMs) to identify different groups with the same trajectories over time. MS profiles were explored using multinomial logistic regression. A total of 16,159 RR patients [1012 (6.26%) presented with LOMS] were analyzed. The GBTM identified four disability trajectories. The group with the most severe EDSS trend included 12.3% of the patients with a mean EDSS score > 4, which increased over time and exceeded 6 score. The group with medium severity EDSS trend comprised 21.9% of the patients and showed a change in EDSS > 3 scores over time. The largest group with 50.8% of patients reported a constant EDSS of 2 score. Finally, the benign group comprised 14.9% of the patients with a low and constant EDSS of 1 score over time. The probability of being in the worst groups increased if the patient was male; had LOMS or experienced brainstem, spinal, or supratentorial symptoms. Four MS severity profiles among RRMS patients in the IMSR have been reported, with LOMS being associated with a rapid worsening of EDSS scores. These findings have important implications for recognizing and managing how older age, aging, and age-related factors interact with MS and its evolution.
Sections du résumé
BACKGROUND
BACKGROUND
Generally infrequent, multiple sclerosis (MS) with late onset (LOMS) is characterized by an onset over the age of 50 and a mainly progressive course, while relapsing-remitting (RR) forms are less frequently observed and explored. This study aimed to characterize a large cohort of MS patients with RRMS at onset to assess the baseline factors related to the worst disability trajectories and explore the role of LOMS.
METHODS
METHODS
The data were extracted from the Italian MS Register (IMSR). Disability trajectories, defined using at least two and up to twenty expanded disability status scale (EDSS) assessments annually performed, were implemented using group-based trajectory models (GBTMs) to identify different groups with the same trajectories over time. MS profiles were explored using multinomial logistic regression.
RESULTS
RESULTS
A total of 16,159 RR patients [1012 (6.26%) presented with LOMS] were analyzed. The GBTM identified four disability trajectories. The group with the most severe EDSS trend included 12.3% of the patients with a mean EDSS score > 4, which increased over time and exceeded 6 score. The group with medium severity EDSS trend comprised 21.9% of the patients and showed a change in EDSS > 3 scores over time. The largest group with 50.8% of patients reported a constant EDSS of 2 score. Finally, the benign group comprised 14.9% of the patients with a low and constant EDSS of 1 score over time. The probability of being in the worst groups increased if the patient was male; had LOMS or experienced brainstem, spinal, or supratentorial symptoms.
CONCLUSIONS
CONCLUSIONS
Four MS severity profiles among RRMS patients in the IMSR have been reported, with LOMS being associated with a rapid worsening of EDSS scores. These findings have important implications for recognizing and managing how older age, aging, and age-related factors interact with MS and its evolution.
Identifiants
pubmed: 38172380
doi: 10.1007/s00415-023-12152-9
pii: 10.1007/s00415-023-12152-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Dobson R, Giovannoni G (2019) Multiple sclerosis—a review. Eur J Neurol 26(1):27–40
doi: 10.1111/ene.13819
pubmed: 30300457
Koch-Henriksen N, Thygesen LC, Stenager E, Laursen B, Magyari M (2018) Incidence of MS has increased markedly over six decades in Denmark particularly with late onset and in women. Neurology 90(22):e1954–e1963
doi: 10.1212/WNL.0000000000005612
pubmed: 29720546
Prosperini L, Lucchini M, Ruggieri S, Tortorella C, Haggiag S, Mirabella M, Pozzilli C, Gasperini C (2022) Shift of multiple sclerosis onset towards older age. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2022-329049 .
doi: 10.1136/jnnp-2022-329049
pubmed: 36522154
Vaughn CB, Jakimovski D, Kavak KS et al (2019) Epidemiology and treatment of multiple sclerosis in elderly populations. Nat Rev Neurol 15(6):329–342
doi: 10.1038/s41582-019-0183-3
pubmed: 31000816
Naseri A, Nasiri E, Sahraian MA, Daneshvar S, Talebi M (2021) Clinical features of late-onset multiple sclerosis: a systematic review and meta-analysis. Mult Scler Relat Disord 50:102816
doi: 10.1016/j.msard.2021.102816
pubmed: 33571792
Lotti CBC, Oliveira ASB, Bichuetti DB, Castro I, Oliveira EML (2017) Late onset multiple sclerosis: concerns in aging patients. Arq Neuropsiquiatr 75(7):451–456
doi: 10.1590/0004-282x20170070
pubmed: 28746432
Tremlett H, Devonshire V (2006) Is late-onset multiple sclerosis associated with a worse outcome? Neurology 67(6):954–959
doi: 10.1212/01.wnl.0000237475.01655.9d
pubmed: 17000960
Confavreux C, Vukusic S (2006) Natural history of multiple sclerosis: a unifying concept. Brain 129(Pt 3):606–616
doi: 10.1093/brain/awl007
pubmed: 16415308
Cree BA, Gourraud PA, Oksenberg JR et al (2016) Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol 80(4):499–510
doi: 10.1002/ana.24747
pubmed: 27464262
pmcid: 5105678
Lublin FD, Häring DA, Ganjgahi H et al (2022) How patients with multiple sclerosis acquire disability. Brain 145(9):3147–3161
doi: 10.1093/brain/awac016
pubmed: 35104840
pmcid: 9536294
Graves JS, Krysko KM, Hua LH, Absinta M, Franklin RJM, Segal BM (2023) Ageing and multiple sclerosis. Lancet Neurol 22(1):66–77
doi: 10.1016/S1474-4422(22)00184-3
pubmed: 36216015
Trojano M, Bergamaschi R, Amato MP et al (2019) The Italian multiple sclerosis register. Neurol Sci 40(1):155–165
doi: 10.1007/s10072-018-3610-0
pubmed: 30426289
Lublin FD, Reingold SC, Cohen JA et al (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83(3):278–286
doi: 10.1212/WNL.0000000000000560
pubmed: 24871874
pmcid: 4117366
Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452
doi: 10.1212/WNL.33.11.1444
pubmed: 6685237
Nagin DS (2014) Group-based trajectory modeling: an overview. Ann Nutr Metab 65(2–3):205–210
doi: 10.1159/000360229
pubmed: 25413659
Jones BL, Nagin DS (2013) A note on a Stata plugin for estimating group-based trajectory models. Sociol Methods Res 42:608–613
doi: 10.1177/0049124113503141
Roxburgh RH, Seaman SR, Masterman T et al (2005) Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 64(7):1144–1151. https://doi.org/10.1212/01.WNL.0000156155.19270.F8
doi: 10.1212/01.WNL.0000156155.19270.F8
pubmed: 15824338
Tur C, Moccia M, Barkhof F et al (2018) Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. Nat Rev Neurol 14(2):75–93
doi: 10.1038/nrneurol.2017.171
pubmed: 29326424
Lynch S, Baker S, Nashatizadeh M, Thuringer A, Thelen J, Bruce J (2021) Disability measurement in Multiple Sclerosis patients 55 years and older: what is the Expanded Disability Status Scale really telling clinicians? Mult Scler Relat Disord 49:102724
doi: 10.1016/j.msard.2020.102724
pubmed: 33609959
Ostolaza A, Corroza J, Ayuso T (2021) Multiple sclerosis and aging: comorbidity and treatment challenges. Mult Scler Relat Disord 50:102815
doi: 10.1016/j.msard.2021.102815
pubmed: 33581613
Lorefice L, Frau J, Coghe G, Pitzalis R et al (2019) Assessing the burden of vascular risk factors on brain atrophy in multiple sclerosis: a case- control MRI study. Mult Scler Relat Disord. 27:74–78
doi: 10.1016/j.msard.2018.10.011
pubmed: 30343253
Sanai SA, Saini V, Benedict RH et al (2016) Aging and multiple sclerosis. Mult Scler 22(6):717–725
doi: 10.1177/1352458516634871
pubmed: 26895718
Makhani N, Tremlett H (2021) The multiple sclerosis prodrome. Nat Rev Neurol 17(8):515–521
doi: 10.1038/s41582-021-00519-3
pubmed: 34155379
pmcid: 8324569
Deems NP, Leuner B (2020) Pregnancy, postpartum and parity: resilience and vulnerability in brain health and disease. Front Neuroendocrinol 57:100820
doi: 10.1016/j.yfrne.2020.100820
pubmed: 31987814
pmcid: 7225072
Magyari M (2016) Gender differences in multiple sclerosis epidemiology and treatment response. Dan Med J 63(3):B5212
pubmed: 26931196
D’Amico E, Patti F, Zanghì A, Chisari CG, Lo Fermo S, Zappia M (2018) Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study. Eur J Neurol 25(12):1425–1431
doi: 10.1111/ene.13745
pubmed: 29956427
Magyari M, Koch-Henriksen N (2022) Quantitative effect of sex on disease activity and disability accumulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 93(7):716–722
doi: 10.1136/jnnp-2022-328994
pubmed: 35393340
Giefing-Kröll C, Berger P, Lepperdinger G, Grubeck-Loebenstein B (2015) How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell 14(3):309–321
doi: 10.1111/acel.12326
pubmed: 25720438
pmcid: 4406660
Tiftikcioglu BI, Ilgezdi I, Zorlu Y, Sener U, Tokucoglu F (2018) Long-term disability and progression in spinal onset multiple sclerosis. Acta Neurol Belg 118(2):217–225
doi: 10.1007/s13760-017-0828-1
pubmed: 28812249
Signori A, Izquierdo G, Lugaresi A et al (2018) Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. Mult Scler 24(5):642–652
doi: 10.1177/1352458517703800
pubmed: 28382837
Signori A, Lorscheider J, Vukusic S et al (2023) Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network. J Neurol Neurosurg Psychiatry 94(1):23–30
doi: 10.1136/jnnp-2022-329987
pubmed: 36171104
Portaccio E, Bellinvia A, Fonderico M et al (2022) Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. Brain 145(8):2796–2805
doi: 10.1093/brain/awac111
pubmed: 35325059
Amato MP, Fonderico M, Portaccio E et al (2020) Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain 143(10):3013–3024
doi: 10.1093/brain/awaa251
pubmed: 32935843
Iaffaldano P, Lucisano G, Caputo F, Italian MS Register et al (2021) Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Disord 14:17562864211019574
doi: 10.1177/17562864211019574
pubmed: 34104220
pmcid: 8170278
Weideman AM, Tapia-Maltos MA, Johnson K, Greenwood M, Bielekova B (2017) Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front Neurol 8:577
doi: 10.3389/fneur.2017.00577
pubmed: 29176956
pmcid: 5686062
Buscarinu MC, Reniè R, Morena E et al (2022) Late-onset MS: Disease course and safety-efficacy of DMTS. Front Neurol 13:829331
doi: 10.3389/fneur.2022.829331
pubmed: 35356454
pmcid: 8960027
Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162–173
doi: 10.1016/S1474-4422(17)30470-2
pubmed: 29275977
Polman CH, Reingold SC, Edan G et al (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.” Ann Neurol 58(6):840–846
doi: 10.1002/ana.20703
pubmed: 16283615
Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302
doi: 10.1002/ana.22366
pubmed: 21387374
pmcid: 3084507
Hauser SL, Cree BAC (2020) Treatment of multiple sclerosis: a review. Am J Med 133(12):1380-1390.e2
doi: 10.1016/j.amjmed.2020.05.049
pubmed: 32682869
pmcid: 7704606